TruScreen Group Limited (NZX: TRU) Board Appointment

Tuesday 2nd March 2021

TruScreen Board Appointment

• Fisher & Paykel Healthcare’s Dr Dexter Cheung joins as Non-Executive Director

• Mr Chris Lawrence retires

Truscreen Group Limited (TruScreen or Company) is pleased to announce the appointment of Dr. Dexter Cheung as a non-executive director of TruScreen.

Dr. Cheung is an experienced medical device engineer and specialist in product research and development, with more than 20 years’ experience. He is the Research & Development Manager of the respiratory humidification division of Fisher & Paykel Healthcare, an NZX/ASX listed healthcare company and a global leader in respiratory medical devices.

Dr Cheung’s technical background in opto-electronics and expertise in medical device engineering is highly relevant to TruScreen whose cervical cancer screening device harnesses optical and electrical signatures for screening results.

Dr. Cheung holds a first-class honours degree in Bachelor of Technology, a Master of Engineering (first class honours) degree and a Doctor of Philosophy (in physics) from his alma mater, University of Auckland.

Mr. Chris Lawrence has also announced his retirement from the board due to health reasons. Shareholders would recall that Mr. Lawrence was unable to attend the last annual shareholders general meeting in August 2020 for health reasons.

Tony Ho, Chairman commented “On behalf of the board, I thank Chris Lawrence for his unstinting contributions to the board over the past four years.

Please see the link below for details:

TruScreen Board Appointment

Source: TruScreen Group Limited

Comments from our readers

No comments yet